A Dutch court injunction blocking Merck (MRK) from manufacturing and selling subcutaneous Keytruda in eight European countries puts legal risk around a flagship cancer drug in sharper focus for shareholders.
Merck’s share price has pulled back over the last month, with a 30 day share price return of down 5.02%. However, momentum over a longer window remains firm, with a 90 day share price return of 14.17% and a 1 year total shareholder return of 70.12%.
Scan how Merck’s legal setback compares with peers by reviewing the hand picked 31 resilient stocks with low risk scores that some investors use when they want steadier balance sheets alongside complex drug pipelines.
Merck now combines a 5% pullback over 30 days with a 70% total return over 12 months and a fresh legal overhang on subcutaneous Keytruda. Does that balance still skew in favour of taking risk at today’s price, once valuation enters the frame?
Most Popular Narrative: 8% Undervalued
Merck last closed at $142.79, while the most followed narrative pins fair value at $155.68. This frames the recent pullback against a still supportive long term story built around pipeline breadth rather than a single cancer franchise.
Merck plans to bring over 20 new growth drivers to market in the coming years, and management now points to more than US$70b in non risk adjusted mid 2030s revenue potential from this next generation portfolio, which could support revenue and earnings resilience through and after the KEYTRUDA loss of exclusivity.
See why 409 investors see Merck as 8% undervalued.
Result: Fair Value of $155.68 (UNDERVALUED)
Still, the Merck story can change quickly if the broader oncology pipeline underdelivers after the KEYTRUDA loss of exclusivity, or if further safety setbacks emerge in newer assets.
Find out about the key risks to this Merck narrative.
Another View: Merck Looks Expensive On Earnings
Merck screens as undervalued against that $155.68 narrative fair value, yet the P/E ratio near 111x tells a very different story when you compare it with the US Pharmaceuticals industry at 15.1x and an estimated fair ratio of 51.4x.
That gap implies investors are already paying a heavy premium for future profit growth, which raises the question of how much upside is left if expectations soften or execution slips on the broader pipeline.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed messages on Merck so far, with rich earnings multiples and legal headaches set against pipeline optimism, mean you should pressure test the data yourself and move quickly to shape your own stance by weighing the 2 key rewards and 5 important warning signs.
Looking for more Merck investment ideas beyond this story?
If Merck is already on your radar, use this moment to widen your opportunity set and pressure test your portfolio against other potential candidates.
- Hunt for quality at a discount by checking the 29 high quality undervalued stocks that some investors watch when they want potential upside with stronger fundamentals.
- Build a steadier income stream by reviewing the 8 dividend fortresses that highlights companies combining higher yields with resilience.
- Strengthen the foundation of your holdings by scanning the list of solid balance sheet and fundamentals (25 results) that can help identify businesses with more robust financial footing.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com